Opinion|Videos|November 15, 2024
Combination Therapies in BRAF-Positive NSCLC
Panelists discuss their insights on current and emerging combination strategies in the treatment of BRAF-positive NSCLC, focusing on the integration of targeted therapies, immunotherapies, or both.
Advertisement
- Dr Gadgeel: What are your thoughts on the current and emerging combination strategies in BRAF- positive NSCLC treatment, particularly those involving targeted therapies, immunotherapies, or both? (
Planchard D, et al. NPJ Precis Oncol. 2024 )
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5































